Market Overview
The Australia Biosimilar Market reached a size of USD 741.6 Million in 2024 and is anticipated to grow significantly to USD 5,512.5 Million by 2033. The market expansion is driven by supportive government policies including PBS listings and increased acceptance by healthcare providers. Clinical trial activities and the growing need for affordable biologic treatments also contribute to steady market growth. This dynamic landscape is marked by greater biosimilar adoption across multiple therapeutic areas.
https://www.imarcgroup.com/australia-biosimilar-market
How AI is Reshaping the Future of Australia Biosimilar Market
- AI-driven data analytics enhance clinical trial design and patient recruitment, improving the efficiency and quality of biosimilar validation studies, reinforcing Australia’s strong clinical research environment.
- Government schemes like the Pharmaceutical Benefits Scheme (PBS) listing have been streamlined with AI tools to manage drug evaluations and subsidization processes, improving patient access.
- AI-powered digital platforms support ongoing physician education and patient awareness programs that encourage biosimilar adoption by simplifying complex data and promoting informed prescribing.
- Real-world data collected through AI-enabled health monitoring helps validate biosimilar safety and effectiveness, increasing healthcare provider confidence in switching from originator biologics.
- AI integration in supply chain optimization aids local manufacturing potential by forecasting demand and managing inventory, reducing dependency on international logistics.
- Leading companies such as Alvotech and Sandoz leverage AI in their biosimilar development pipelines, accelerating time-to-market and fostering competitive strategies.
Grab a sample PDF of this report: https://www.imarcgroup.com/australia-biosimilar-market/requestsample
Australia Biosimilar Market Growth Factors
The Australia biosimilar market is strongly driven by the patent expiry of high-cost biologics, allowing more affordable alternatives to enter the market and foster competition. This patent expiry encourages manufacturers both local and international to develop biosimilars for chronic and critical conditions such as cancer and rheumatoid arthritis. The presence of regulatory clarity and expedited approval mechanisms further facilitates rapid market entry. These factors collectively lead to increased pricing pressures favoring biosimilars, reshaping competitive landscapes and expanding market share, particularly as biosimilars replace originator biologics across various therapeutic domains.
Australia is witnessing a significant rise in chronic diseases including cancer, autoimmune disorders, and diabetes, which demand long-term biologic therapies. The high costs of originator products have historically limited patient access, but biosimilars provide comparable efficacy and safety at more affordable price points. Both public and private healthcare sectors increasingly rely on biosimilars to reduce long-term treatment expenses and enhance accessibility. Accompanied by growing physician confidence and government support, biosimilars have become essential in sustainable healthcare strategies aimed at meeting the expanding demand for chronic disease management.
Private sector investment is bolstering market growth as pharmaceutical companies increase their focus on biosimilar development and commercialization in Australia. Favorable regulatory environments and rising demand for cost-effective biologics are attractive to both start-ups and established firms. These companies are expanding local operations, forming collaborations, and investing in clinical trials and manufacturing capabilities. Enhanced private investment stimulates innovation, market competition, and supply security, thereby improving affordability and access to advanced biologic therapies, which in turn supports overall sector growth.
Australia Biosimilar Market Segmentation
Molecule Insights:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
- Pegfilgrastim
- Trastuzumab
- Bevacizumab
- Others
Manufacturing Type Insights:
- In-house Manufacturing
- Contract Manufacturing
- Indication Insights:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
- Others
Regional Insights:
- Australia Capital Territory & New South Wales
- Victoria & Tasmania
- Queensland
- Northern Territory & Southern Australia
- Western Australia
Key Players
- Amgen
- Sandoz
- Celltrion
- Alvotech
- Cipla
- Samsung Bioepis
- Polpharma Biologics
Recent Development & News
- April 2025: Sandoz’s Tyruko became the first biosimilar to natalizumab approved in Australia by TGA, indicated for relapsing remitting multiple sclerosis. Sandoz holds exclusive commercialization rights through its 2019 agreement with Polpharma Biologics, enhancing market access and treatment options.
- April 2025: Celltrion’s denosumab biosimilars, Stoboclo and Osenvelt, received approval from Australia’s Therapeutic Goods Administration (TGA), marking Celltrion as the second sponsor with approved biosimilars, signaling intensified market competition and innovation.
- February 2025: TGA approved Uteknix, a biosimilar to Stelara® (ustekinumab) by Alvotech and Cipla, in 90 mg and 45 mg formulations for moderate to severe plaque psoriasis and psoriatic arthritis, increasing affordable treatment availability and broadening therapeutic choices.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
https://www.imarcgroup.com/request?type=report&id=31900&flag=F
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302